Crenezumab

Crenezumab
Crenezumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target 1-40-β-amyloid
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 1174395-19-7 N
ATC code None
Chemical data
Formula C6442H9966N1706O2018S40 
Mol. mass 144.88 kDa
 N(what is this?)  (verify)

Crenezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.[1]

Crenezumab was developed by Genentech, Inc.

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Crenezumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/crenezumab.pdf. 
v · d · eMonoclonals for bone, musculoskeletal, circulatory, and neurologic systems
Bone ("-os-", "-s(o)-")
Human ("-osu-")
Humanized ("-sozu-")
Blosozumab • Romosozumab
Musculoskeletal ("-mul-")
Human ("-mulu-")
Circulatory ("-c(i[r])-")
Human ("-ciru-")
Icrucumab • Ramucirumab • Vesencumab
Mouse ("-ciro-")
Biciromab‡ • Imciromab‡
Chimeric ("-cixi-")
Humanized ("-cizu-")
Alacizumab pegol • Bevacizumab/Ranibizumab • Etaracizumab • Tadocizumab
Neurologic ("-ne(u)(r)-")
Human ("-neru-")
Atinumab • Fulranumab • Gantenerumab
Humanized ("-nezu-"/"-neuzu-")
Bapineuzumab† • Crenezumab • Ponezumab • Solanezumab • Tanezumab
Angiogenesis inhibitor ("-anibi-")
Humanized ("-anibizu-")
#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III


Stub icon This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.